LSTA

+ Watchlist + Portfolio

Lisata Therapeutics, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $1.12
52-Week Range: $0.99 – $5.07
Market Cap: $10.09M
P/E (TTM): —
EPS (TTM): -1.64
Dividend Yield: —

Advanced Metrics

Price/Book: 1.24
PEG Ratio: 118.40
Return on Equity: -101.66%
Return on Assets: -56.74%
Gross Margin: 100.00%
Operating Margin: -16426.00%
Profit Margin: 0.00%
Current Ratio: 3.69
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-8.10M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $-604.75K

LSTA Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$1.00M	$170.00K
Research & Development	$43.46M	$12.73M	$11.33M	$7.95M
Selling, General & Admin	$14.14M	$12.97M	$12.07M	$10.43M
Operating Expenses	$57.60M	$25.71M	$23.41M	$18.38M
Operating Income	-$57.60M	-$25.71M	-$22.41M	-$18.21M
EBITDA	-$57.53M	-$25.52M	-$22.23M	-$18.06M
Pretax Income	-$56.70M	-$23.17M	-$20.78M	-$17.55M
Income Tax	-$2.48M	-$2.33M	-$798.00K	-$962.00K
Net Income	-$54.23M	-$20.84M	-$19.98M	-$16.59M
Diluted EPS	-10.47	-2.58	-2.40	-1.91
Diluted Shares	5.18M	8.07M	8.33M	8.69M

LSTA Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$32.15M	$22.59M	$16.21M	$15.96M
Receivables	—	$0.00	$900.00K	$0.00
Current Assets	$71.88M	$53.92M	$34.58M	$17.70M
Total Assets	$73.03M	$54.69M	$35.00M	$17.74M
Current Liabilities	$6.38M	$6.59M	$5.61M	$3.07M
Total Debt	$485.00K	$168.00K	$137.00K	$0.00
Total Liabilities	$6.71M	$6.80M	$5.68M	$3.14M
Retained Earnings	-$507.24M	-$528.08M	-$548.07M	-$564.65M
Shareholders' Equity	$66.58M	$48.15M	$29.57M	$14.86M
Working Capital	$65.49M	$47.33M	$28.96M	$14.63M

LSTA Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$21.17M	-$20.03M	-$19.36M	-$15.95M
Capital Expenditure	-$285.00K	—	—	-$28.00K
Free Cash Flow	-$21.45M	-$20.03M	-$19.36M	-$15.98M
Depreciation & Amortisation	$69.00K	$189.00K	$174.00K	$146.00K
Stock-Based Compensation	$2.64M	$2.04M	$1.65M	$1.23M
Investing Cash Flow	$28.91M	$10.10M	$13.23M	$15.09M
Financing Cash Flow	-$224.00K	$385.00K	-$206.00K	$599.00K
Net Change in Cash	$7.52M	-$9.54M	-$6.33M	-$264.00K

LSTA Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$70.00K	$0.00	$100.00K	$0.00
Research & Development	$2.60M	$2.25M	$1.96M	$1.13M	$1.20M
Selling, General & Admin	$3.25M	$2.69M	$2.46M	$2.04M	$3.74M
Operating Expenses	$5.85M	$4.94M	$4.41M	$3.18M	$4.94M
Operating Income	-$5.85M	-$4.87M	-$4.41M	-$3.08M	-$4.94M
EBITDA	-$5.80M	-$4.82M	-$4.37M	-$3.06M	-$4.94M
Pretax Income	-$5.69M	-$4.66M	-$4.25M	-$2.95M	-$4.88M
Income Tax	-$962.00K	$0.00	$0.00	$0.00	-$387.00K
Net Income	-$4.72M	-$4.66M	-$4.25M	-$2.95M	-$4.49M
Diluted EPS	-0.55	-0.54	-0.49	—	-0.50
Diluted Shares	8.60M	8.61M	8.74M	—	9.01M

LSTA Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$20.22M	$16.84M	$19.00M	$15.96M	$13.06M
Receivables	$750.00K	$501.00K	$502.00K	$0.00	—
Current Assets	$28.62M	$24.89M	$21.57M	$17.70M	$14.02M
Total Assets	$28.98M	$25.16M	$21.76M	$17.74M	$14.06M
Current Liabilities	$3.81M	$4.31M	$4.57M	$3.07M	$3.31M
Total Debt	$92.00K	$47.00K	$0.00	$0.00	—
Total Liabilities	$3.88M	$4.38M	$4.64M	$3.14M	$3.39M
Retained Earnings	-$552.79M	-$557.45M	-$561.70M	-$564.65M	-$569.14M
Shareholders' Equity	$25.36M	$21.03M	$17.37M	$14.86M	$10.93M
Working Capital	$24.81M	$20.57M	$17.01M	$14.63M	$10.71M

LSTA Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$5.40M	-$3.96M	-$3.34M	-$3.25M	-$3.08M
Capital Expenditure	-$28.00K	—	—	—	—
Free Cash Flow	-$5.43M	-$3.96M	-$3.34M	-$3.25M	-$3.08M
Depreciation & Amortisation	$43.00K	$44.00K	$44.00K	$15.00K	$2.00K
Stock-Based Compensation	$530.00K	$239.00K	$232.00K	$225.00K	$364.00K
Investing Cash Flow	$9.43M	$505.00K	$5.15M	$0.00	$0.00
Financing Cash Flow	-$23.00K	$64.00K	$353.00K	$205.00K	$181.00K
Net Change in Cash	$4.01M	-$3.39M	$2.16M	-$3.04M	-$2.90M

Market Snapshot

About

Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of solid tumors and other serious diseases. The company uses its proprietary platform to enhance drug delivery and efficacy in oncology applications. Lisata is advancing its lead programs through clinical trials targeting pancreatic cancer and other difficult-to-treat malignancies.